ArticleMedicine2026
Clinical outcomes of arterial detection ligation technique for grade II/III versus grade IV hemorrhoidal disease.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Doppler-guided dearterialization with mucopexy is well established for grade II/III hemorrhoidal disease (HD), whereas evidence supporting its use in grade IV disease remains limited. The arterial detection ligation (ADL) system provides deeper Doppler penetration and improved arterial mapping, potentially enhancing outcomes in advanced disease. This study compared clinical outcomes of ADL-mucopexy between patients with grade II/III and grade IV HD. Patients who underwent ADL-mucopexy between July 2022 and March 2024 were retrospectively analyzed. Patients were classified into grade II/III and grade IV groups according to the Goligher classification. Primary outcomes included postoperative pain and recurrence, while secondary outcomes comprised operative time, tenesmus, bowel function parameters, and patient satisfaction. Seventy-eight patients were included (grade II/III: n = 54; grade IV: n = 24). Patients with grade IV disease had significantly longer baseline toilet sitting times and symptom duration. Operative time and hospital stay were also longer in the grade IV group, while the number of mucopexies and external excisions was similar. Postoperatively, grade IV patients required more opioid analgesia, experienced longer times to first flatus and defecation, and reported higher 24-hour visual analog scale pain scores. Tenesmus at 1 week was more common in grade IV patients. Despite these early differences, 1-month satisfaction scores were comparable between groups (8.8 vs 8.5). Recurrence was observed in 1 patient in each group during follow-up. ADL-mucopexy demonstrated comparable short-term clinical outcomes and patient satisfaction across different HD grades. Although patients with grade IV disease experienced greater early postoperative discomfort, recurrence rates and overall satisfaction were similar. ADL-mucopexy may be considered a potential minimally invasive surgical option in carefully selected patients with grade IV HD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.